Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Firm”), at present introduced that it has accomplished its trial entitled “A Part 1, Randomised, Double-Blind, Placebo-Managed, A number of Ascending Dose Examine to Consider the Security and Pharmacokinetics of Lucid-21-302 in Wholesome Grownup Contributors.” A last security assessment committee (“SRC”) assembly was held after completion of the trial. The SRC discovered that Lucid-21-302 “(Lucid-MS”) was well-tolerated with no security issues and no severe hostile occasions have been reported in the course of the trial.
Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound for the therapy of a number of sclerosis (“MS”). It’s a patented New Chemical Entity (“NCE”) that has a singular mechanism of motion. As proven in preclinical fashions of MS, it might immediately stabilize the myelin sheath surrounding nerve fibers and thus present safety from demyelination. MS is a illness characterised by demyelination, a course of that causes progressive incapacity.
“Our medical improvement crew is thrilled that this Part 1 trial is now full, and that Lucid-MS was deemed secure and well-tolerated in wholesome contributors,” mentioned Dr. Andrzej Chruscinski, Vice-President, Scientific and Scientific Affairs at Quantum Biopharma. “This marks an necessary milestone and permits for the following steps within the medical improvement of Lucid-MS.”
Zeeshan Saeed, CEO of Quantum BioPharma added, “We’re enthusiastic about potential of Lucid-MS to guard myelin in MS sufferers because it represents a brand new route within the therapy of this illness. By finishing this trial and demonstrating security in wholesome contributors, we at the moment are nearer to initiating a Part 2 trial of Lucid-MS in folks with MS.
“We at the moment are looking forward to our Part 2 trial as we work in direction of our targets of drug approval and commercialization of Lucid-MS. We look ahead to offering additional updates as we execute on our milestones, pushed by our mission to arrest demyelination in MS,” concluded Saeed.
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical firm devoted to constructing a portfolio of modern belongings and biotech options for the therapy of difficult neurodegenerative and metabolic problems and alcohol misuse problems with drug candidates in several levels of improvement. Via its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is concentrated on the analysis and improvement of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity proven to forestall and reverse myelin degradation, the underlying mechanism of a number of sclerosis, in preclinical fashions. Quantum BioPharma invented unbuzzd™ and spun out its OTC model to an organization, Celly Vitamin Corp. (“Celly Vitamin”), led by trade veterans. Quantum BioPharma retains possession of 25.71% (as of June 30, 2024) of Celly Vitamin at www.unbuzzd.com. The settlement with Celly Vitamin additionally consists of royalty funds of seven% of gross sales from unbuzzd™ till funds to Quantum BioPharma complete $250 million. As soon as $250 million is reached, the royalty drops to three% in perpetuity. Quantum BioPharma retains 100% of the rights to develop comparable merchandise or various formulations particularly for pharmaceutical and medical makes use of. Quantum BioPharma maintains a portfolio of strategic investments by means of its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or business property. For extra data go to www.quantumbiopharma.com.
Ahead Wanting Data
This press launch incorporates sure “forward-looking statements” throughout the that means of relevant Canadian securities regulation. Any statements that categorical or contain discussions with respect to predictions, expectations, beliefs, plans, projections, goals, assumptions or future occasions or efficiency (usually, however not at all times, recognized by phrases or phrases resembling “believes”, “anticipates”, “expects”, “is anticipated”, “scheduled”, “estimates”, “pending”, “intends”, “plans”, “forecasts”, “targets”, or “hopes”, or variations of such phrases and phrases or statements that sure actions, occasions or outcomes “could”, “might”, “would”, “will”, “ought to” “would possibly”, “will probably be taken”, or “happen” and comparable expressions) are usually not statements of historic truth and could also be forward-looking statements. The forward-looking data and forward-looking statements contained herein embrace, however are usually not restricted to, statements relating to: the Firm’s give attention to the analysis and improvement of Lucid-MS to forestall and reverse myelin degradation; the Firm’s Lucid-21-302 medical improvement program in a number of sclerosis advancing in direction of human phase-2 efficacy trials; the Firm’s intention to retain 100% of the rights to develop merchandise for pharmaceutical and medical makes use of; the Firm’s intention to keep up a portfolio of strategic investments by means of FSD Strategic Investments Inc.; MZ taking part in a key function in helping the Firm to boost its market consciousness and foster productive, persevering with dialogues with shareholders and different market contributors; MZ being engaged by the Firm for the MZ Preliminary Interval; MZ working with the Firm to develop and implement a complete capital markets technique designed to extend the Firm’s visibility all through the funding group; MZ marketing campaign highlighting how Quantum BioPharma is growing a strong pipeline of merchandise and belongings targeted on addressing important unmet wants in mind problems and alcohol well being; and the Firm’s method to remedies in mind problems and alcohol well being representing an amazing income potential.
Ahead-looking data on this information launch are based mostly on sure assumptions and anticipated future occasions, specifically: the Firm’s evaluation of market circumstances, its capacity to achieve market share, and its potential aggressive edge are correct; the Firm can have the power to hold out its plans with respect to its new innovation and choices, together with its capacity to conduct analysis and improvement of Lucid-MS; the Firm’s Lucid-21-302 medical improvement program in a number of sclerosis will advance in direction of human phase-2 efficacy trials; the Firm will retain 100% of the rights to develop comparable product or various formulations particularly for pharmaceutical and medical makes use of; the Firm will search new enterprise alternatives; the Firm will improve effectivity in its processes and partnerships; the Firm can have the power to hold out its different targets and goals the Firm’s intention to keep up a portfolio of strategic investments by means of FSD Strategic Investments Inc.; MZ will play a key function in helping the Firm to boost its market consciousness and foster productive, persevering with dialogues with shareholders and different market contributors; MZ will probably be engaged by the Firm for the MZ Preliminary Interval; MZ will work with the Firm to develop and implement a complete capital markets technique designed to extend the Firm’s visibility all through the funding group; the MZ marketing campaign will spotlight how Quantum BioPharma is growing a strong pipeline of merchandise and belongings targeted on addressing important unmet wants in mind problems and alcohol well being; and the Firm’s method to remedies in mind problems and alcohol well being can have an amazing income potential.
These statements contain recognized and unknown dangers, uncertainties and different components, which can trigger precise outcomes, efficiency or achievements to vary materially from these expressed or implied by such statements, together with however not restricted to: the Firm’s incapacity to retain 100% of the rights to develop merchandise for pharmaceutical or medical makes use of; the Firm’s incapacity to boost its product improvement capabilities and/or keep a portfolio of strategic investments; the Firm’s Lucid-21-302 medical improvement program in a number of sclerosis not advancing in direction of human phase-2 efficacy trials; the Firm won’t have the power to hold out its different targets and goals the Firm’s intention to keep up a portfolio of strategic investments by means of FSD Strategic Investments Inc.; MZ won’t play a key function in helping the Firm to boost its market consciousness and foster productive, persevering with dialogues with shareholders and different market contributors; MZ won’t be engaged by the Firm for the MZ Preliminary Interval; MZ won’t work with the Firm to develop and implement a complete capital markets technique designed to extend the Firm’s visibility all through the funding group; the MZ marketing campaign won’t spotlight how Quantum BioPharma is growing a strong pipeline of merchandise and belongings targeted on addressing important unmet wants in mind problems and alcohol well being; the Firm’s method to remedies in mind problems and alcohol well being won’t have an amazing income potential; and the dangers mentioned within the Firm’s Annual Report on Kind 20-F for the fiscal yr ended December 31, 2023, last quick kind base shelf prospectus dated December 22, 2023 and registration assertion on Kind F-3 containing a base shelf prospectus, every below the heading “Threat Components”. These components needs to be thought-about fastidiously, and readers shouldn’t place undue reliance on the forward-looking statements. Readers are cautioned that the foregoing listing shouldn’t be exhaustive. Though the forward-looking statements contained on this press launch are based mostly upon what administration believes to be cheap assumptions, the Firm can not guarantee readers that precise outcomes will probably be per these forward-looking statements. Ahead-looking statements contained on this information launch are expressly certified by this cautionary assertion and mirror the Firm’s expectations as of the date hereof and are topic to vary thereafter. The Firm undertakes no obligation to replace or revise any forward-looking statements, whether or not because of new data, estimates or opinions, future occasions, or outcomes or in any other case or to clarify any materials distinction between subsequent precise occasions and such forward-looking data, besides as required by relevant regulation.
The reader is urged to confer with further data regarding Quantum BioPharma, together with its annual data kind, might be situated on the SEDAR+ web site at www.sedarplus.ca and on the EDGAR part of america Securities and Change Fee’s web site at www.sec.gov for a extra full dialogue of such danger components and their potential results.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Govt Co-Chairman of the Board
E mail: Zsaeed@quantumbiopharma.com
Phone: (833) 571-1811
Investor Relations
Chris Tyson
Govt Vice President
MZ North America
Direct: 949-491-8235
QNTM@mzgroup.us
www.mzgroup.us
